Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1802||SWOG||Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAZ171||ECOG-ACRIN||Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women||Cancer Prevention and Control CIRB||Available to Open|
|ANZGOG-0902-GOG-0274||GOG||A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091105||Alliance||A Phase III; Double Blind; Randomized; Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)||Adult CIRB - Late Phase Emphasis||Available to Open|
|10058||ETCTN||A Phase I Study of talimogene laheparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum||Adult CIRB - Early Phase Emphasis||Available to Open|
|ANBL00B1||COG||Neuroblastoma Biology Studies||Pediatric CIRB||Available to Open|
|A091605||Alliance||A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6141||ECOG-ACRIN||Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|9903||ETCTN||A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor||Adult CIRB - Early Phase Emphasis||Available to Open|
|AAML1531||COG||Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study||Pediatric CIRB||Available to Open|